Increased BMI can adversely affect response to agents such as VEGF inhibitors [146], endocrine therapy in breast cancer [144], hematologic chemotherapy toxicity in gynecologic cancer [142], and outcomes after SBRT for prostate cancer [147]. This evidence concerns the gene VEGFA and prostate cancer.